Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 3.380
+0.030 (0.90%)
Aug 4, 2026, 4:27 PM CET
Nykode Therapeutics AS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.45 | 9.16 | 13.32 | 9.03 | 35.77 | |
Revenue Growth | -95.05% | -31.26% | 47.56% | -74.76% | -83.42% |
Gross Profit | 0.45 | 9.16 | 13.32 | 9.03 | 35.77 |
Selling, General & Admin | 13.55 | 31.04 | 27.48 | 18.05 | 16.85 |
Depreciation & Amortization Expenses | 2.04 | 2.25 | 2.12 | 1.81 | 0.74 |
Other Operating Expenses | 13.45 | 24.2 | 41.8 | 42.33 | 28.96 |
Total Operating Expenses | 29.04 | 57.49 | 71.41 | 62.19 | 46.54 |
Operating Income | -28.59 | -48.33 | -58.08 | -53.16 | -10.78 |
Interest Income | 13.29 | 9 | 18.67 | 8.64 | 4.13 |
Interest Expense | -2.4 | -6.18 | -4.68 | -6.46 | -4.48 |
Total Non-Operating Income (Expense) | 10.89 | 2.82 | 14 | 2.17 | -0.34 |
Pretax Income | -17.7 | -45.51 | -44.09 | -50.98 | -11.12 |
Provision for Income Taxes | -5.46 | -6.69 | -8.93 | -8.24 | -1.7 |
Net Income | -12.24 | -38.82 | -35.15 | -42.74 | -9.41 |
Net Income to Common | -12.24 | -38.82 | -35.15 | -42.74 | -9.41 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 327 | 327 | 301 | 290 | 286 |
Shares Outstanding (Diluted) | 327 | 327 | 301 | 290 | 286 |
Shares Change | - | 8.66% | 3.58% | 1.32% | -3.31% |
EPS (Basic) | -0.04 | -0.12 | -0.12 | -0.15 | -0.03 |
EPS (Diluted) | -0.04 | -0.12 | -0.12 | -0.15 | -0.03 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -29.49 | -51.29 | -98.53 | -23.37 | 0.28 |
Free Cash Flow Growth | - | - | - | - | -99.84% |
Free Cash Flow Per Share | -0.09 | -0.16 | -0.33 | -0.08 | 0.00 |
Dividends Per Share | - | 0.088 | - | - | - |
Dividend Growth | - | - | - | - | - |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -6310.82% | -527.75% | -435.95% | -588.73% | -30.13% |
Profit Margin | -2701.99% | -423.90% | -263.86% | -473.40% | -26.32% |
FCF Margin | -6510.82% | -560.07% | -739.52% | -258.81% | 0.79% |
EBITDA | -26.55 | -46.08 | -55.96 | -51.34 | -10.04 |
EBITDA Margin | -5860.71% | -503.17% | -420.03% | -568.63% | -28.07% |
EBIT | -28.59 | -48.33 | -58.08 | -53.16 | -10.78 |
EBIT Margin | -6310.82% | -527.75% | -435.95% | -588.73% | -30.13% |
Effective Tax Rate | 30.84% | 14.70% | 20.26% | 16.16% | 15.33% |